Clene Business Update
Clene Inc. entered into a subaward amendment with NYU for the fourth year of a previously announced NIH grant, providing up to $7.2 million in funding. The grant supports an Expanded Access Program for the company's CNM-Au8 treatment for amyotrophic lateral sclerosis (ALS). This represents the final year of a total $45.1 million four-year grant awarded under the ACT for ALS Act.
- Counterparty
- New York University
- Term
- Sept 2026 to Aug 2027